Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

Read More

Ligand Reports Second Quarter 2019 Financial Results

Read More

Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range